Nyxoah S.A. (NYXH) Financial Analysis & Valuation | Quarter Chart
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.... more
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solut... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $135.10M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Instruments & Supplies |
| Country | BE | CEO | Olivier Taelman |
| IPO Date | 2021-04-28 | CAGR | — |
| Employees | 154 | Website | www.nyxoah.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NYXH chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $145.90M | P/E | -0.54 | Forward P/E | -1.94 | PEG | — |
| P/S | 0.66 | P/B | 0.27 | P/CF | -0.29 | P/FCF | -0.21 |
| Sales | $26.20M | Sales 1Y | 359.21% | Sales 3Y | 645.9% | Sales 5Y | 5242.69% |
| EPS | $-2.52 | EPS 1Y | 2.84% | EPS 3Y | 30.72% | EPS 5Y | 123.71% |
| Sales QoQ | 4.25% | EPS QoQ | 56.76% | Sales QoQ Avg | 67.02% | EPS QoQ Avg | 6.92% |
| Gross Margin | 51.31% | Operating Margin | -383.05% | Profit Margin | -434.72% | ROCE | -71.6% |
| ROA | -58% | ROE | -180% | Altman Z Score | -3.06 | Piotroski Score | 2 |
| Current Ratio | 2.38 | Quick Ratio | 2.31 | Cash Ratio | 1.36 | Op. CF Ratio | -0.35 |
| Debt/Equity | 0.63 | Debt/Assets | 0.31 | Lt Debt/Equity | 0.35 | Lt Debt/Cap. | 0.25 |
| Intrst Cov. | -5.73 | Inventory Turnover | 2.98 | Asset Turnover | 0.13 | Receivables Turnover | 2.28 |
| Enterprise Value | $145.90M | P/E Ratio | -0.54 |
| Forward P/E | -1.94 | PEG Ratio | — |
| P/S Ratio | 0.66 | P/B Ratio | 0.27 |
| P/CF Ratio | -0.29 | P/FCF Ratio | -0.21 |
| EPS | $-2.52 | EPS Growth 1Y | 2.84% |
| EPS Growth 3Y | 30.72% | EPS Growth 5Y | 123.71% |
| Revenue Growth 1Y | 359.21% | Gross Margin | 51.31% |
| Operating Margin | -383.05% | Profit Margin | -434.72% |
| ROE | -180% | ROA | -58% |
| ROCE | -71.6% | Current Ratio | 2.38 |
| Quick Ratio | 2.31 | Cash Ratio | 1.36 |
| Debt/Equity | 0.63 | Interest Coverage | -5.73 |
| Altman Z Score | -3.06 | Piotroski Score | 2 |
Nyxoah S.A. (NYXH) valuation & financials
Nyxoah S.A. (NYXH) has a market capitalization of $135.10M and trades at a price-to-earnings ratio of -0.5. It operates in the Healthcare sector (Medical - Instruments & Supplies).
Nyxoah S.A.'s revenue grew +359.2% over the last year.
Nyxoah S.A.'s next earnings report is scheduled for November 5, 2026 after market close (provider scheduled date); analysts estimate EPS of $-0.35. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)